, Departments of a Pediatrics, b Medicine, T lineage acute lymphoblastic leukemia (T-ALL) is characterized by aberrant clonal proliferation and tissue invasion of lymphoblasts (reviewed in ref. 1) . Although intensive treatment protocols have markedly improved the outcomes of children and adolescents with T-ALL, cure rates for adults remain below 50%, and the prognosis is poor for patients who relapse at any age (1, 2) . Modern treatment regimens also carry a substantial risk of adverse late effects (3) . Thus, the development of more effective and less toxic therapies that are based on the underlying molecular lesions is a high priority.
Recent studies have advanced our understanding of T-ALL pathogenesis (reviewed in refs. [4] [5] [6] . Genes encoding transcription factors, such as TAL1, LYL1, LMO1, and LMO2, are frequently deregulated by chromosomal translocations in T-ALL (7) . NOTCH1 was first implicated in leukemogenesis through a t (7;9) chromosomal translocation that truncates and constitutively activates the Notch1 protein (8) , and gain-of-function NOTCH1 mutations within the heterodimerization (HD) and/or proline-, glutamic acid-, serine-, and threonine-rich (PEST) domains are found in ≈55% of primary human T-ALL specimens (9) . Emerging data also support an important role for aberrant Ras signaling in T-ALL. NRAS and KRAS2 mutations are found in 10-15% of cases (10, 11) , whereas the NF1 tumor suppressor gene is inactivated in ≈3% (12) . Chromosomal translocations that result in fusions of ABL and JAK2, kinases that are known to activate Ras, are also found in T-ALL (11) . More recently, somatic gain-offunction JAK1 mutations were discovered in 18-27% of adult and in 2% of pediatric T-ALL cases, respectively (13, 14) . These leukemias demonstrated elevated levels of phosphorylated ERK and Akt, which are important effectors of activated Ras. The PTEN tumor suppressor, which encodes a lipid phosphatase that negatively regulates the phosphoinosityl 3-kinase (PI3K)/Akt signaling pathway, is mutated in 5-8% of T-ALLs, and reduced expression was observed in an additional 17% of cases (15, 16) . Recent studies that uncovered PI3K pathway mutations in ≈50% of pediatric T-ALLs underscore the central role of this Ras effector cascade in leukemic growth (17) (18) (19) .
Observations in mice further implicate hyperactive Ras in T-ALL pathogenesis. Transgenic mice overexpressing Nras or Rasgrp1 develop T lineage lymphomas (20, 21) . In addition, thymic lymphomas are observed in ≈30% of mice harboring a latent oncogenic Kras G12D allele that is activated by spontaneous recombination (22) . Furthermore, the observation that most of these mice do not develop T-ALL infers that additional mutations are required. Using the IFN-regulated Mx1-Cre transgene to activate a conditional mutant Kras LSL-G12D allele in hematopoietic cells causes an aggressive myeloproliferative disease (MPD) (23, 24) . Interestingly, transferring bone marrow from these mice into irradiated recipients results in T-ALL (25, 26) , and limit dilution experiments showed that one to three Kras mutant hematopoietic stem cells were sufficient to initiate T-ALL in vivo (26, 27) . Consistent with data from other murine T-ALL models, these leukemias acquired somatic Notch1 mutations (4, 25, 26, 28) .
Retroviral insertional mutagenesis (RIM) in mice is a robust strategy that has been used to identify genes that are involved in human leukemia, including Ikzf1 (Ikaros), Notch1, and Lmo2 in T-ALL (29) (30) (31) (32) . We used the MOL4070LTR retrovirus (33) to perform RIM in Mx1-Cre, Kras G12D mice. Here we show that aberrant Ikaros expression due to viral integrations is a frequent early event and that somatic Notch1 mutations arise later and cooperate with oncogenic Kras in leukemogenesis. We generated a large panel of tumor-derived cell lines for biochemical and preclinical studies. Analysis of Ras and Notch1 signaling uncovered unexpected heterogeneity in T-ALL cell lines and in primary leukemias. Exposing T-ALL cells to targeted agents in vitro and in vivo uncovered markers of drug response and revealed synergistic effects of γ-secretase with MAP/ERK kinase (MEK) or PI3K/mammalian target of rapamycin (mTOR) inhibitors. These data demonstrate the value of using diverse panels of related cancers for identifying and ordering mutations, To whom correspondence may be addressed. E-mail: shannonk@peds.ucsf.edu.
This article contains supporting information online at www.pnas.org/cgi/content/full/ 1001064107/DCSupplemental. interrogating cancer signaling networks, and discovering molecular markers of drug sensitivity. G12D expression was then activated at 3 weeks of age by administering a single dose of polyinosinic-polycytidilic acid (pIpC). All Kras G12D mice that were infected with MOL4070LTR developed MPD without overt evidence of acute leukemia. We reasoned that the rapid progression of the MPD might provide insufficient time for retrovirally induced hematologic malignancies to emerge. To test this idea, we exploited the fact that the Kras G12D -induced MPD is not transplantable into sublethally irradiated mice (23, 24) and transferred bone marrow cells from 48 moribund Kras G12D mice into 3-5 recipients that received 450 cGy of radiation (Fig. 1A) . We refer to bone marrow donors with MPD as "virus-injected mice" throughout this article. Twenty bone marrows from virus-injected mice (42%) induced T-ALL, and nine others (19%) resulted in transplantable myeloid malignancies ( Fig.  1A and Fig. S1 ). By contrast, the frequencies of T-ALL and myeloid malignancies in Kras WT littermates that received MOL4070LTR and were observed for ≈15 months were 21% and 51%, respectively (Fig. 1A) . Latency was determined by adding the time to death from MPD in the virus-injected mice and the time to the development of a myeloid malignancy (Fig. 1B) or T-ALL (Fig. 1C) in transplant recipients. Kras G12D expression reduced acute myeloid leukemia latency from 336 to 122 days (P < 0.0001; Fig. 1B ) and T-ALL latency from 226 to 151 days (P < 0.001; Fig. 1C ).
Results

MOL4070LTR Induces T-ALL in
Primary recipients with T-ALL showed a large thymic mass, modest leukocytosis with lymphoblasts visible on blood smears, and extensive infiltration of multiple tissues (Fig. S2) . T-ALL cells of thymic origin readily induced T-ALL in secondary recipients (Fig. 1D) . Kras G12D and Kras WT T-ALLs from primary and secondary recipient mice are arrested at an immature stage of development, and most express CD4 and CD8. Southern blot analysis of primary T-ALLs revealed a clonal integration pattern that was not detected in the marrows of donor virus-injected mice ( Fig. 1 D and  E) . Interestingly, a single donor bone marrow could initiate independent T-ALLs in different primary recipients ( Fig. 1 D and E) , which invariably demonstrated a stable pattern of retroviral insertions in secondary transplants ( Fig. 1 D and F) . Secondary recipients developed aggressive leukemia with reduced latency, bone marrow effacement, and variable infiltration of the thymus.
MOL4070LTR Integrations Disrupt the Ikzf1 Locus in Kras
G12D T-ALLs.
We cloned retroviral integration sites from 24 Kras G12D T-ALLs and 6 Kras WT T-ALLs (Table S1 ). The criteria used to define common insertion sites (CIS) were (i) genes must be identified in at least two independent tumors; (ii) an individual integration must be recovered more than five times (of 192 independent sequenced clones per T-ALL); and (iii) one integration must be within 30 kb upstream/downstream of the identified gene. Ikzf1 (Ikaros) was the most frequent CIS (n = 9) and was restricted to Kras G12D tumors. All nine integrations were within the Ikzf1 gene, and most were predicted to disrupt Ikaros function (Table  S1) . Consistent with this, RT-PCR analysis of leukemias with Ikzf1 integrations revealed aberrant cDNA expression. Western blotting demonstrated absence of the high-molecular-weight Ikaros protein, which is associated with full biologic activity, and expression of truncated dominant negative Ikaros isoforms (Fig.  S3A) . Interestingly, whereas Kras G12D T-ALLs without Ikzf1 insertions showed robust expression of the high-molecularweight form of Ikaros (n = 3), thymus lysates from Kras G12D mice without T-ALL unexpectedly showed reduced expression of this isoform (Fig. S3A ). We performed a retroviral transduction/ transplantation experiment to assess the effect of expressing a dominant negative Ikaros isoform in Kras mutant bone marrow cells (32, 34) . Recipient mice that were transplanted with these cells developed T-ALL (Fig. S3B) .
We identified three other CIS including Rasgrp1 integrations, which occurred in three of six of the Kras WT tumors and are likely to be functionally redundant with Kras G12D expression (Table S1 ).
Somatic Notch1 Mutations in MOL4070LTR-Induced T-ALLs. Western blotting with an antibody that detects the Notch1 intracellular domain (NICD) revealed evidence of pathway activation in 90% of primary Kras G12D T-ALLs ( Fig. 2A) , and sequence analysis identified truncating PEST domain mutations that are similar to those observed in human T-ALL (Table S2) . We detected Notch1 mutations in all 30 Kras G12D T-ALLs examined. By contrast, only 3 of 9 Kras WT T-ALLs (33%) contained Notch1 mutations. Similarly, all 11 Kras G12D T-ALL cell lines shown in Table 1 carried Notch1 mutations, compared with 1 of 5 Kras WT lines. As expected, each cell line harbored the same mutation as the parental T-ALL. Interestingly, however, we observed variable levels of NICD in T-ALL cell lines with Notch1 mutations, including a number in which NICD was not visualized by Western blotting (Fig. 2B, lanes 12, 13, 15 , and 17, and Table 1) .
To further assess the relationship of Notch1 mutations and NICD protein expression to Notch pathway activation, we used quantitative real-time PCR to assay the Notch target genes Deltex1 and Hes1 in seven T-ALL cell lines (Fig. 2C) . Elevated Deltex1 expression was observed in two cell lines in which NICD was visualized by Western blotting but not in three lines with Notch1 mutations that lacked NICD (Fig. 2C ). As expected, Deltex1 expression was not detected in two T-ALL cell lines without Notch1 mutations (Fig. 2C) . Although less dramatic, Hes1 expression demonstrated a similar overall pattern, with the highest levels observed in the two cell lines with detectable NICD (Fig.  2C) . Together, these data support the idea that NICD is a biochemical marker of Notch pathway activation in T-ALL cell lines. The coexistence of retroviral integrations and Notch1 mutations in individual T-ALLs allowed us to ascertain the likely order in which these genetic changes were acquired. The outcome shown in Fig. 1 D and E, in which a single virus-injected Kras G12D bone marrow gave rise to genetically distinct T-ALLs, was especially informative. In these cases, each T-ALL carried a different Notch1 mutation. Further analysis using allele-specific PCR did not detect Notch1 mutations in the bone marrows of virus-injected mice (Fig. S4) . On the basis of the sensitivity of these assays, it is formally possible that ≈200 or fewer cells of the 2 × 10 6 that were transplanted could have harbored a Notch1 mutation. Together, these studies provide strong evidence for sequential acquisition of Ikzf1, Kras, and Notch1 mutations during leukemogenesis and support the idea that Notch1 mutations are acquired after transplantation.
Signaling in T-ALL Cell Lines. We interrogated Ras signaling in cell lines generated from Kras WT and Kras G12D T-ALLs (Table 1) . KRas G12D accumulates in the active, GTP-bound conformation and exerts its oncogenic effects, in part, by deregulating the Raf1/ MEK/ERK and PI3K/Akt/mTOR/S6 effector pathways. Kras G12D T-ALL cell lines uniformly showed markedly elevated levels of Ras-GTP compared with lines generated from Kras WT leukemias (Fig. 3A) . However, the levels of phosphatase and tensin homolog (PTEN) and of phosphorylated ERK, Akt, and S6 (p-ERK, p-Akt, and p-S6) were highly variable in cell lines of both Kras genotypes, and changes in "upstream" pathway components were not highly correlated with downstream proteins. For example, absent or reduced PTEN expression was not uniformly associated with increased p-Akt and p-S6 levels (Fig. 3B) . Western blot analysis also revealed variable levels of p-ERK, p-Akt, p-S6, and PTEN in primary T-ALLs (Fig. 3C) . By contrast, Kras G12D expression in untransformed primary thymocytes consistently induced ERK and S6 activation (Fig. 3C) . The striking biochemical heterogeneity in Kras G12D T-ALLs indicates that oncogenic K-Ras G12D signaling is modulated in the context of multistep tumorigenesis.
Sensitivity of Kras
G12D and Kras WT T-ALL Cell Lines to Chemical
Inhibitors. Notch1 activation requires cleavage by the γ-secretase protease. Importantly, because many T-ALL-associated Notch1 mutant proteins remain dependent on γ-secretase for biologic activity, treatment with γ-secretase inhibitors (GSIs) is a rational therapeutic strategy for T-ALL (4). We investigated the effects of Compound E, a potent GSI, on the proliferation of T-ALL cell lines. These studies revealed variable sensitivity, which correlated poorly with the presence of a mutation in either Notch1 or Kras (Table 1) . However, 10 cell lines in which NICD was detected by Western blotting were sensitive to Compound E, whereas none of 6 lines without visible NICD were sensitive (Table 1 , Fig. 4A , and Fig. S5 ).
We also evaluated the effects of the dual-specificity PI3K/ mTOR inhibitor PI-103 (35) on the proliferation of T-ALL cell lines and found that all were sensitive to 1 μM of this drug, irrespective of Kras genotype or pathway activation as deter- 
mined by Western blotting (Figs. 3B and 4B, Table 1 , and Fig. S6  A and B) . By contrast, there was substantial variability in the responses of T-ALL cell lines to the MEK inhibitor PD0325901. Interestingly, Kras G12D T-ALL cell lines showed enhanced sensitivity to PD0325901, which was independent of p-ERK levels (Figs. 3B and 4C, Table 1 , and Fig. S6 C and D) .
Most cell lines that were sensitive to Compound E were also sensitive to PD0325901 (Table 1) . We therefore examined whether either inhibitor influences both targets. However, PD325901 had no effect on cleaved Notch1 levels, and Compound E did not reduce p-ERK levels (Fig. S7) . The finding that many of the same cell lines were sensitive to PD0325901 and Compound E suggested that blocking both pathways might lead to an enhanced therapeutic effect. Indeed, there is an additive effect on proliferation when these inhibitors are combined at low doses ( Fig. 4D and Fig. S8A) . Similarly, exposing cells lines to both PI-103 and Compound E increased the inhibitory effects of either drug alone (Fig. 4D and Fig. S8B ).
PD0325901 Treatment of Primary T-ALLs. To test the prediction that
Kras genotype might influence MEK dependence in vivo, we established cohorts of eight recipient mice that were transplanted with each of six primary Kras G12D or three Kras WT T-ALLs (n = 72 total recipients). Five mice in each group were randomly assigned to treatment with PD0325901, and three received control vehicle. The mice were treated for 4 weeks or until death. Consistent with data from the T-ALL cell lines, therapeutic response to MEK inhibition was associated with the Kras G12D genotype (Fig. 4E ). Whereas treatment with PD0325901 was associated with a significant increase in median survival in recipients that were injected with Kras G12D T-ALLs (P > 0.0005), this inhibitor had no beneficial effect on the Kras WT T-ALLs (Fig. 4E) . As in human cancer, there was considerable variability among individual T-ALLs with respect to aggressiveness and degree and duration of response.
Discussion
We dissected the molecular events involved in T-ALL pathogenesis and tested potential therapeutic strategies in a diverse panel of T-ALLs generated by RIM. Ikaros is essential for lymphoid development and is mutated or aberrantly expressed in human T and B lineage ALL (36, 37) . Our data implicating aberrant Ikaros expression as an initiating event in T lineage leukemia are consistent with previous studies in genetically engineered mice (38) . Beverly and Copabianco (32) performed a RIM screen in transgenic mice that express a potent NICD allele (N IC mice) and recovered Ikzf1 as a CIS. They also showed that expressing mutant Ikaros proteins in N IC bone marrow rapidly induced T-ALL in irradiated recipients (32) . Subsequent studies also revealed somatic Notch1 PEST domain mutations in Ikaros transgenic mice (39, 40) .
In contrast to previous RIM studies (30, 41) , we found that Notch1 activation invariably resulted from PEST domain mutations rather than from retroviral integrations within the Notch1 locus. A study in which Chiang et al. (28) used a transduction/ transplantation system to compare a series of Notch1 mutant alleles suggests an explanation for this finding. These authors showed that truncated Notch1 proteins generated as a result of chromosomal translocations or retroviral integrations within the Notch1 gene are much more potent than PEST domain mutations. These data raise the possibility that truncated Notch1 alleles may be initiating or early events in T-ALL, whereas biologically "weaker" HD and PEST domain mutations may be obligate cooperating events (4, 28) . Our data support this hypothesis. We identified Ikzf1 disruption as an early event that cooperates strongly with subsequent oncogenic Kras expression in T lineage leukemogenesis (Fig. 5A) . Furthermore, RT-PCR analysis of independent T-ALLs that emerged from the same virus-injected mouse provided strong evidence that Notch1 mutations are acquired after transplantation (Fig. 5A) . On the basis of these results, we hypothesize that antecedent Ikzf1 and Kras mutations create a field of thymocytes with aberrant proliferation, survival, and/or differentiation that only require a Notch1 PEST domain mutation to induce full leukemic transformation.
The combinatorial effects of Ikzf1, Kras
G12D
, and Notch1 mutations on cellular signaling networks are unknown, and molecular markers of responses to targeted agents have not been defined. Whereas KRas G12D protein expression resulted in markedly elevated Ras-GTP levels, we unexpectedly observed great variability in the activation of downstream effectors. It is possible that T lymphoid cells adapt to the stress of oncogenic K-Ras expression by modulating effector pathways and that cooperating mutations either antagonize or potentiate this adaptive response. Alternatively, mutations that initiate T-ALL could partially dictate the biochemical consequences of a subsequent Ras gene mutation. These potential mechanisms are not mutually exclusive, and our data demonstrate the profound biochemical complexity of primary cancers that arise because of multiple interacting mutations.
Our analysis of a large panel of murine T-ALL cell lines uncovered a complex pattern of GSI response that is consistent with the heterogeneous responses of human T-ALL lines (9) . We unexpectedly found a poor correlation between the presence of a Notch1 mutation and GSI sensitivity and instead identified NICD expression as a highly predictive biomarker of drug response. T-ALL clones that acquire Notch1 mutations in vivo uniformly express NICD (Fig. 2A) ; however, NICD expression is no longer detected in many tumor-derived cell lines (Fig. 2B,  lanes 12, 13, 15, and 17 ). This apparent paradox is not due to widespread clonal infidelity, given that Southern blot analysis of Our observation that T-ALL cell lines with Notch1 mutations can survive and proliferate in the absence of NICD expression also suggests outgrowth of a Notch1-indpendent clone as a potential mechanism of acquired GSI resistance. Despite variable activation of downstream effector pathways in individual T-ALLs, we found that a Kras mutant genotype correlated with sensitivity to the MEK inhibitor PD0325901. This is in contrast to our experience with GSI treatment, whereby a biochemical marker (NICD expression) predicted drug sensitivity but the presence of a Notch1 mutation did not. The relationship between the tumor-associated mutation and the protein targets of PD0325901 and Compound E may explain this difference (Fig. 5B ).
In cancers with oncogenic Kras mutations that are treated with a MEK inhibitor, the biochemical target is a downstream component of a signaling cascade, which is subject to extensive feedback regulation that may dramatically alter p-ERK levels. Despite this modulation, our data indicate that the Kras mutant T-ALL cells remain dependent on MEK. By contrast, GSIs interfere with the production of a protein that is encoded by mutant Notch1. As such, NICD levels provide a biomarker that directly reflects the functional output of the mutant allele. It follows that growth of T-ALL cells that no longer contain NICD would be insensitive to GSI treatment.
Our data have implications for understanding the biology of T-ALL and improving the treatment of this aggressive cancer. Mutations or rearrangements in KRAS, NRAS, NF1, PTEN, PIK3R1, PIK3CA, AKT, ABL, and JAK1 occur in ≈60% of T-ALL (10) (11) (12) (13) (15) (16) (17) (18) (19) , and identifying mutations in other signaling proteins may uncover new therapeutic targets. The uniform sensitivity of our diverse panel of cell lines to a PI3K inhibitor is consistent with emerging genetic data implicating deregulated PI3K/PTEN/Akt signaling as playing a pivotal role in T lineage leukemogenesis (15) (16) (17) (18) (19) . Together, these studies and the observed synergy between Compound E and PI-103 support initiating preclinical and clinical trials of PI3K pathway inhibitors-both alone and in combination with GSIs-in T-ALL.
We have identified NICD expression as a potential biomarker for assessing clinical responsiveness to GSIs. This may be particularly relevant in two contexts. First, human T-ALLs that do not express elevated levels of NICD at diagnosis may not respond to GSI treatment irrespective of NOTCH1 mutation status. Second, our data support the idea that human T-ALLs with elevated levels of NICD are likely to respond to GSI treatment, and that this will be associated with reduced NICD levels. An intriguing question is whether tumors that subsequently relapse will reactivate NICD expression even in the face of GSI exposure or will acquire the capacity to proliferate PEST domain mutations result in the production of mutant Notch1 proteins that remain dependent on γ-secretase for proteolytic cleavage and biologic activity. NICD levels therefore provide a direct biochemical readout of the deleterious effects of a Notch1 mutation, and the ability of GSI treatment to reduce these levels is a robust marker of drug response. G12D T-ALLs. Mice were transplanted with three independent primary Kras WT (Left) or six independent Kras G12D (Right) T-ALLs and were treated with vehicle (dashed line) or PD0325901 (solid line). There was no significant difference in the survival (in days) of mice engrafted with Kras WT leukemias (P = 0.13). In contrast, PD0325901 treatment increased survival in recipients of Kras G12D TALLs (P < 0.0005). Kras WT vehicle n = 7, Kras WT PD0325901 n = 13, Kras G12D vehicle n = 15, and Kras G12D PD0325901 n = 30.
without NICD. Studies of this nature would shed light on potential mechanisms of acquired drug resistance. On the other hand, our observation that tumor genotype (i.e., Kras
) was a more important determinant of response to the MEK inhibitor PD0325901 than the biochemical readout of p-ERK levels suggests that cancer cells can remain dependent on a specific upstream mutation despite heterogeneous effects on pathway components. These data, in turn, infer that it will be important to compare potential biochemical and genetic biomarkers to predict how cancers will respond to drugs that do not directly target mutant oncoproteins. Insertional mutagenesis is a powerful strategy for approaching the genetic and biochemical complexity of human cancer, for harnessing "chemical genetic" strategies to correlate tumor biology with therapeutic responses, and for generating diverse reagents for preclinical trials of specific agents that can inform human treatment protocols.
Materials and Methods
Mice. All animal experiments conformed to national regulatory standards and were approved by the University of California, San Francisco Committee on Animal Research. C57Bl6/129Sv F1 pups were injected with MOL4070LTR intraperioneally at 3-5 days of age and with pIpC at 21 days of age. For adoptive transfer of acute leukemias, 2 × 10 6 cells were injected retroorbitally into 8-12 week old wild-type C57Bl6/129Sv F1 recipient mice that had been irradiated with 450 cGy.
Southern Analysis. Genomic DNA was digested with HindIII, followed by electrophoresis and capillary transfer to Hybond-N filters (Amersham). Filters were hybridized with a MOL4070 LTR probe that was labeled with radioactive α-dCTP using Rediprime II (Amersham).
T-ALL Cell Lines. Single-cell suspensions were plated in lymphocyte media (DME-H21, 20% FBS, 10 mM Hepes, penicillin/streptomycin, L-glutamine, 50 μM β-mercaptoethanol, nonessential amino acids, sodium pyruvate, 10 ng/mL IL-2, and 10 ng/mL IL-7). For proliferation assays, 3-5 × 10 5 cells were plated per well in a 24-well plate in lymphocyte media plus drug or DMSO (vehicle). After a minimum of four cell doublings in vehicle wells, cells were counted on a Vi-Cell XR (Beckman-Coulter). Cell counts were then normalized to vehicle treated cells.
Preclinical Studies. T-ALL transplant recipients with evidence of leukemia were randomly assigned to receive PD0325901 at a dose of 5 mg/kg per day by oral gavage or a control vehicle. Mice were weighed weekly to adjust the dose and observed daily during treatment (28 days).
Other Methods. Procedures for Shotgun cloning, retroviral transduction and adoptive transfer, Western blotting, Notch1 mutation analysis, and quantitative RT-PCR can be found in SI Materials and Methods.
